Seeking Alpha

More on Deutsche Bank's GlaxoSmithKline (GSK +1.8%) upgrade: Analyst Mark Clark says FY13...

More on Deutsche Bank's GlaxoSmithKline (GSK +1.8%) upgrade: Analyst Mark Clark says FY13 guidance "looks achievable," and notes that the regulatory environment should be favorable regarding melanoma, HIV, and especially respiratory drug candidates. Additionally, the pipeline may be underappreciated, he says.
Comments (4)
  • TwistTie
    , contributor
    Comments (2476) | Send Message
     
    I love underappreciated pipelines.
    28 May 2013, 10:52 AM Reply Like
  • biochemist
    , contributor
    Comments (354) | Send Message
     
    Don't we all. ;-)
    28 May 2013, 05:17 PM Reply Like
  • Smallstep
    , contributor
    Comments (942) | Send Message
     
    I agree. Hard to find goodies these days. ----Small
    28 May 2013, 08:54 PM Reply Like
  • Michael Bryant
    , contributor
    Comments (5582) | Send Message
     
    Buy (BMY).
    28 May 2013, 10:17 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector